Rong Stephanie Huang
Department of Medicine, Section of Hematology and Oncology
University of Chicago, USA
BS in Pharmacy from Shanghai Medical University
MS and PhD in Clinical Pharmacy from Purdue University
Post doctoral/Clinical Pharmacology Fellowship training at the University of Chicago
Dr. Huang is an Assistant Professor of Medicine; Director, the Pharmacogenomics of Anticancer Agents Research (PAAR) Cell Line Core; Member, Committee on Clinical Pharmacology and Pharmacogenomics, the University of Chicago Comprehensive Cancer Center, Center for Personalized Therapeutics, Committee on Cancer Biology and Faculty Oversight Committee for Pharmacology Core facility.
Dr. Huang is a Member of American Association for Cancer Research (AACR), American Society of Human Genetics (ASHG) and American Society of Clinical Pharmacology and Therapeutics (ASCPT). She serves on the editorial board of Genomics, Proteinomics and Bioinformatics, and as a reviewer for Behavioral and Brain Functions, Clinical Pharmacology & Therapeutics, Genetic Epidemiology, Human Mutation, Pharmacogenomics, Journal of Cellular & Molecular Medicine, Pharmacogenetics & Genomics, Neoplasia, Molecular Cancer Therapeutics, Drug Metabolism and Disposition and Pharmacotherapy .
Her research focuses on translational pharmacogenomic research with particular interest in the pharmacogenomics of anticancer agents. By systematically evaluating the human genomes and their relationships to drug response and toxicity, her goal is to develop clinically useful models that predict risks for adverse drug reactions and non-response prior to administration of chemotherapy. They utilize cell lines (derived from healthy and disease individuals as well as commercially available cancer cell lines), and clinical samples to discover and functional characterize genetic variations, gene and microRNA (miRNA) expression for their role in chemotherapeutic sensitivity.